HSK47977 / Haisco - LARVOL DELTA

Orally bioavailable BCL6 degrader HSK47977 featuring a novel CRBN ligand demonstrates potent antitumor activity and synergy with BCL2 inhibition in NHL (AACR 2026) - "Abstract is embargoed at this time."

Late-breaking abstract • Non-Hodgkin’s Lymphoma • Oncology • BCL6 • CRBN

A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

…Innovative drug HSK47977 tablets have received FDA approval for clinical trials (FUTU) - "HSK47977 tablets are an oral BCL6 (B-cell lymphoma 6 protein) PROTAC small molecule formulation independently developed by Haishi Ke, capable of targeting, binding, and degrading BCL6 protein, thereby inhibiting the occurrence and development of tumor cells, with the aim of treating lymphoma."

IND • Lymphoma

BCL6 degrader with novel CRBN ligand demonstrates promising selectivity and preclinical efficacy alone or in combination with BCL2 inhibitor (AACR 2025) - "In summary, these findings underscore HSK47977 as a potent and orally bioavailable BCL6 degrader, distinguished by its novel CRBN ligand. Moreover, the strategic combination with a BCL2 inhibitor is poised to significantly augment the therapeutic efficacy, offering a promising approach for the treatment of diffuse large B-cell lymphoma."

Combination therapy • IO biomarker • Preclinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • BCL6 • CRBN • GSPT1 • IKZF1 • SALL4